SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Trump Says Anthropic No Longer Seen as National Security Threat 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
NEW YORK, Jan. 20, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of shareholders of Vital Therapies, Inc. (“Vital Therapies”) (NASDAQ:VTL) who purchased their shares between April 17, 2014 and August 21, 2015.
The complaint alleges that throughout the class period, defendants issued materially false and misleading statements and/or failed to disclose material information regarding the Company’s ELAD System studies, VTI-208, VTI-210, and VTI-212, including (a) the studies’ independent significance; (b) the degree to which the studies were interrelated; and (c) that in the case of the failure of the VTI-208 trial, the Company would not continue the VTI-210 trial.
On August 21, 2015, after the market closed, Vital Therapies announced that the VTI-208 trial had “failed to meet the primary endpoint of overall survival through at least 91 days…” and that the Company would stop the VTI-210 and VTI-212 clinical trials. Upon this news, Vital Therapies shares plunged 73.4% to close at just $3.65 per share the next trading day.
If you suffered a loss in Vital Therapies you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/vital-therapies.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
